Skip to Content

AstraZeneca PLC AZN Stock Quote

| Rating as of

XLON:AZN

Morningstar‘s Stock Analysis AZN

Valuation
Currency in GBX
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

AstraZeneca Remains Well Positioned for Strong Growth Based on a Broad Drug Portfolio

Damien Conover, CFA Sector Director

Business Strategy and Outlook

| Damien Conover, CFA |

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The replenishment of new drugs is setting up industry-leading growth.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics AZN

Company Profile AZN

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

Contact
1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, United Kingdom
T +44 2037495000
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 83,100

Related News AZN